| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d84aa8c4818bda002eded1de6d318389 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 |
| filingDate |
2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9bf018ae85083f8d8652174601d41f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc4dea9d5a01642f18a2ecf2f103ea85 |
| publicationDate |
2020-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020119663-A1 |
| titleOfInvention |
Anti-h7n9 fully human monoclonal antibody 4e18, preparation method therefor, and application thereof |
| abstract |
An anti-H7N9 fully human monoclonal antibody 4E18, a preparation method therefor, and an application thereof. Fully human monoclonal antibody 4E18 without containing any murine components is quickly screened by using memory B cells and a PCR method. The antibody can target hemagglutinin (HA) that binds to H7N9 viruses, and has neutralizing activity against H7N9 virus infection; no human anti-mouse antibody reaction would occur, and better biocompatibility is provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111320687-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112079917-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111320687-A |
| priorityDate |
2018-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |